Comparative Efficacy of China's Domestic versus Imported PD-1/PD-L1 Inhibitor-Based Combinations as First-Line Therapy for Advanced Non-small Cell Lung …
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
J Yang, R Min, H Zhong, Y Hu
Available at SSRN 6021360
papers.ssrn.com
Background: Advanced non-small cell lung cancer (NSCLC) imposes a heavy global burden, with the need for optimal first-line programmed cell death protein 1 (PD-1)/cell death protein ligand 1 (PD-L1) inhibitor combination therapies remaining unmet. This study aimed to comprehensively compare the efficacy of approved PD-1/PD-L1 inhibitor combinations, including agents developed in China, to provide evidence-based treatment recommendations. Methods: This systematic review and network meta-analysis followed the …
